BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33939661)

  • 1. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    Chan H; Zhang L; Choti MA; Kulke M; Yao JC; Nakakura EK; Bloomston M; Benson AB; Shah MH; Strosberg JR; Bergsland EK; Van Loon K
    Pancreas; 2021 Apr; 50(4):506-512. PubMed ID: 33939661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
    Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
    Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
    Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
    J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
    Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
    J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Sadowski SM; Millo C; Neychev V; Aufforth R; Keutgen X; Glanville J; Alimchandani M; Nilubol N; Herscovitch P; Quezado M; Kebebew E
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S676-82. PubMed ID: 26350374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
    Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
    Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroenteropancreatic neuroendocrine tumors: Role of surgery.
    Sauvanet A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):175-181. PubMed ID: 31079831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors.
    Singh S; Chan DL; Moody L; Liu N; Fischer HD; Austin PC; Segelov E
    JAMA Oncol; 2018 Apr; 4(4):583-585. PubMed ID: 29543939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
    Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
    J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery for GEP-NETs.
    Knigge U; Hansen CP
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):819-31. PubMed ID: 23582921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
    Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
    Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors.
    Chi W; Warner RRP; Chan DL; Singh S; Segelov E; Strosberg J; Wisnivesky J; Kim MK
    Pancreas; 2018 Mar; 47(3):321-325. PubMed ID: 29401168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical management of neuroendocrine tumors.
    Tamburrino D; Spoletini G; Partelli S; Muffatti F; Adamenko O; Crippa S; Falconi M
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):93-102. PubMed ID: 26971846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET)].
    Aoki T; Kokudo N
    Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2272-9. PubMed ID: 25482902
    [No Abstract]   [Full Text] [Related]  

  • 19. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.
    Chakedis J; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Marincola-Smith P; Cho C; Beems M; Pawlik TM; Maithel SK; Schmidt CR; Dillhoff M
    J Gastrointest Surg; 2019 Jan; 23(1):122-134. PubMed ID: 30334178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature.
    Gaiani F; de'Angelis N; Minelli R; Kayali S; Carra MC; de'Angelis GL
    Medicine (Baltimore); 2019 Sep; 98(37):e17154. PubMed ID: 31517859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.